CLASS: Conjugated Linoleic Acid Supplementation Study

Sponsor

University of Aberdeen (Other)

Overall Status

Completed

CT.gov ID

NCT01234636

Collaborator

(none)

Enrollment

Location

Arms

Duration (Months)

2.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Cardiovascular disease is a major cause of mortality worldwide resulting in one out of three global deaths. One of the main characteristics of cardiovascular disease is impaired blood flow and increased formation of clots. Platelets are clot-forming cells responsible for prevention of bleeding. However, in disease state they may be overly activated and tend to stick to each other, promoting blood clots and blockage of vessels.

Conjugated linoleic acids (CLA) are unique fatty acids present in dairy food products and beef which would help to prevent platelets from clotting and thus help to prevent cardiovascular disease. However, the mechanisms by which those fatty acids affect platelet function are not yet fully understood. We designed a human intervention study assessing the mechanisms by which CLA beneficially affect platelet function and markers of haemostasis and inflammation in humans.

Condition or Disease	Intervention/Treatment	Phase
Cardiovascular Disease	Dietary Supplement: Placebo oil	N/A

Detailed Description

Despite being trans fatty acids, dietary conjugated linoleic acids( CLA) have been associated with decreased atherogenesis, beneficial effects on insulin sensitivity , glucose and lipid profile and body composition in animal studies.Todate only few studies have studied the effects of the two individual CLA isomers on body composition , lipoprotein metabolism immune function , inflammation , insulin sensitivity and oxidative stress in humans.

A previous study revealed that both cis9,trans11 and trans10,cis12 CLA, as well as CLA mix, significantly decreased agonist-induced platelet aggregation and TxB2 production ex vivo compared with linoleic acid. No effect on agonist-induced platelet aggregation or other blood clotting parameters in healthy female volunteers was observed upon supplementation with 3.9 g/d CLA, compared with sunflower oil, but this may have been due to the low number of subjects participating in this study.

Indeed, supplementation with 13.0 g/day of CLA mix - 50:50 blend, compared with placebo oil, significantly decreased fibrinogen levels in type 2 diabetes patients, and fibrinogen and plasminogen activator inhibitor-1 levels were significantly lower upon intervention with CLA milk (4.7 g/d cis9,trans11 CLA and 0.4 g/d trans10,cis12 CLA), compared with CLA mix (2.3 g/d cis9,trans11 CLA and 2.2 g/d trans10,cis12 CLA), and lower compared with olive oil, in postmenopausal women.Thus overall evidence indicates that especially the cis9,trans11 CLA isomer may prevent platelet activation and aggregation, and possibly display anticoagulant properties. However, so far this has not been assessed in detail.

In this study we assess effects of supplementation of cis9,trans11 CLA-rich oil on platelet function by measuring not only platelet aggregation but also in vitro coagulation and platelet activation in healthy overweight humans. In addition, we examine the effects of CLA supplementation on plasma and cellular marker of inflammation and oxidative stress.

Study Design

Study Type:

Interventional

Actual Enrollment :

50 participants

Allocation:

Randomized

Intervention Model:

Factorial Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Prevention

Official Title:

Effects of cis9,trans11 Conjugated Linoleic Acid on Platelet Function, Markers of Haemostasis and Inflammation on Humans

Study Start Date :

Nov 1, 2010

Actual Primary Completion Date :

Nov 1, 2012

Actual Study Completion Date :

Nov 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: cis9,trans 11 CLA oil 50 volunteers on cross over design , receiving 4g/day of cis9,trans11 CLA	Dietary Supplement: Placebo oil Placebo oil of 4g/day
Placebo Comparator: Placebo oil 50 volunteers cross over design, placebo oil 4g/day	Dietary Supplement: Placebo oil Placebo oil of 4g/day

Arm

Intervention/Treatment

Active Comparator: cis9,trans 11 CLA oil

50 volunteers on cross over design , receiving 4g/day of cis9,trans11 CLA

Dietary Supplement: Placebo oil

Placebo oil of 4g/day

Placebo Comparator: Placebo oil

50 volunteers cross over design, placebo oil 4g/day

Dietary Supplement: Placebo oil

Placebo oil of 4g/day

Outcome Measures

Primary Outcome Measures

Change of expression of P-selectin and fibrinogen receptor activation on platelets by flow cytometry [At 2 weeks]
Using fluorescently-conjugated monoclonal antibodies and whole blood flow cytometry after ex vivo stimulation with adenosine diphosphate (ADP), thrombin receptor-activating peptide (TRAP) P-selectin expression as early marker of platelet activation Activated fibrinogen receptor as late marker of platelet activation
Change of in vitro bleeding time using the Platelet Function Analyzer (PFA-100) [At 2 weeks supplementation]
Using collagen-epinephrine coated cartridges Using collagen-adenosine diphosphate coated cartridges
Change of coagulation marker assessed as fibrinogen levels in plasma [At 2 weeks supplementation]
Using semi-automated coagulometer using fibrinogen assay according to Clauss method

Secondary Outcome Measures

Change in light transmission aggregometry of platelet rich plasma induced by collagen and arachidonic acid [At 2 weeks supplementation]
Using a Helena Platelet Aggregation Chromogenic Kinetics System-4 (PACKS-4) light transmission aggregometer
Change in plasma levels of von Willebrand factor (vWF), soluble ICAM (s-ICAM) and soluble P-selectin (sP-selectin) as markers of endothelial activation [At 2 weeks supplementation]
Using enzyme-linked immunoabsorbent assay (ELISA) in plasma

Eligibility Criteria

Criteria

Ages Eligible for Study:

30 Years to 74 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:• Healthy men and women aged 35-74 years

blood pressure below 160/90 mmHg;
fasting plasma glucose < 7 mmol/L;
total cholesterol < 8 mmol/L,with cholesterol/HDL ratio < 6 and/or ASSIGN score < 20%)
platelet count > 170x109/L
haematocrit above 40 % for males and above 35 % for females
haemoglobin above 130 g/L for males and above 115 g/L for females
having a 10-20% risk for developing cardiovascular disease within the next 10 years based on the ASSIGN calculation (http://cvrisk.mvm.ed.ac.uk/index.htm) including the following factors: age, gender, number of cigarettes smoked per day, Scottish Index of Multiple Deprivation (SIMD)/postcode, systolic blood pressure, levels of total and HDL cholesterol and family history of cardiovascular disease or having at least one additional risk factor such as being over 50 years old, BMI above 25 kg/m2, elevated triglyceride levels (> 1.7 mmol/L) or elevated glucose levels (> 5.6 mmol/L);

Exclusion Criteria:Exclusion criteria Subjects are excluded if

They are regularly taking aspirin or aspirin-containing drugs, or other anti-inflammatory drugs;
They are taking drugs or herbal medicines known to alter platelet function or the haemostatic system in general;
They are diagnosed with diabetes, hypertension, renal, hepatic, haematological disease or coronary heart disease;
They are undertaking more than 6 hours vigorous exercise per week
They are pregnant (or planning to become pregnant) or lactating;
They have given a pint of blood for transfusion purposes within the last month;
They have unsuitable veins for blood sampling;
They are inability to understand the participant information sheet or inability to speak, read and understand the English language.